Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Serum cytokines elevated during gluten-mediated cytokine release in coeliac disease.

Goel G, Daveson AJM, Ee HC, Tye-Din JA, Wang S, Szymczak E, Williams LJ, Dzuris JL, Neff KM, Truitt KE, Anderson RP.

Clin Exp Immunol. 2019 Sep 10. doi: 10.1111/cei.13369. [Epub ahead of print]

PMID:
31505020
2.

Elevated serum interleukin-2 after gluten correlates with symptoms and is a potential diagnostic biomarker for coeliac disease.

Tye-Din JA, Daveson AJM, Ee HC, Goel G, MacDougall J, Acaster S, Goldstein KE, Dzuris JL, Neff KM, Truitt KE, Anderson RP.

Aliment Pharmacol Ther. 2019 Sep 4. doi: 10.1111/apt.15477. [Epub ahead of print]

PMID:
31483515
3.

Randomised clinical trial: a placebo-controlled study of subcutaneous or intradermal NEXVAX2, an investigational immunomodulatory peptide therapy for coeliac disease.

Truitt KE, Daveson AJM, Ee HC, Goel G, MacDougall J, Neff K, Anderson RP.

Aliment Pharmacol Ther. 2019 Sep;50(5):547-555. doi: 10.1111/apt.15435. Epub 2019 Aug 13.

PMID:
31407810
4.

Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa.

Parasrampuria DA, Truitt KE.

Clin Pharmacokinet. 2016 Jun;55(6):641-55. doi: 10.1007/s40262-015-0342-7. Review.

5.

Efficacy and safety of colesevelam in combination with pioglitazone in patients with type 2 diabetes mellitus.

Rosenstock J, Truitt KE, Baz-Hecht M, Ford DM, Tao B, Chou HS.

Horm Metab Res. 2014 Dec;46(13):943-9. doi: 10.1055/s-0034-1383648. Epub 2014 Jul 23.

PMID:
25054436
6.

Safety and efficacy of colesevelam HCl in the treatment of elderly patients.

Gavin JR 3rd, Jones MR, Ford DM, Truitt KE.

Drugs Aging. 2014 Jun;31(6):461-70. doi: 10.1007/s40266-014-0174-4.

7.

A 26-week, placebo- and pioglitazone-controlled monotherapy study of rivoglitazone in subjects with type 2 diabetes mellitus.

Chou HS, Truitt KE, Moberly JB, Merante D, Choi Y, Mun Y, Pfützner A.

Diabetes Obes Metab. 2012 Nov;14(11):1000-9. doi: 10.1111/j.1463-1326.2012.01631.x. Epub 2012 Jul 4.

PMID:
22686944
8.

Pharmacological effects of CS-0777, a selective sphingosine 1-phosphate receptor-1 modulator: results from a 12-week, open-label pilot study in multiple sclerosis patients.

Moberly JB, Ford DM, Zahir H, Chen S, Mochizuki T, Truitt KE, Vollmer TL.

J Neuroimmunol. 2012 May 15;246(1-2):100-7. doi: 10.1016/j.jneuroim.2012.03.007. Epub 2012 Mar 31.

PMID:
22465063
9.

Pharmacological modulation of peripheral T and B lymphocytes by a selective sphingosine 1-phosphate receptor-1 modulator.

Moberly JB, Rohatagi S, Zahir H, Hsu C, Noveck RJ, Truitt KE.

J Clin Pharmacol. 2012 Jul;52(7):996-1006. doi: 10.1177/0091270011408728. Epub 2011 May 12.

PMID:
21566200
10.

Diabetic macular edema: correlations with available diabetes therapies--evidence across a qualitative review of published literature from MEDLINE and EMBASE.

Merante D, Menchini F, Truitt KE, Bandello FM.

Drug Saf. 2010 Aug 1;33(8):643-52. doi: 10.2165/11538340-000000000-00000. Review.

PMID:
20635822
11.

A 26-week, placebo- and pioglitazone-controlled, dose-ranging study of rivoglitazone, a novel thiazolidinedione for the treatment of type 2 diabetes.

Truitt KE, Goldberg RB, Rosenstock J, Chou HS, Merante D, Triscari J, Wang AC.

Curr Med Res Opin. 2010 Jun;26(6):1321-31. doi: 10.1185/03007991003715079.

PMID:
20370378
12.

Long-term Safety and Tolerability of Colesevelam HCl in Subjects with Type 2 Diabetes.

Goldfine AB, Fonseca VA, Jones MR, Wang AC, Ford DM, Truitt KE.

Horm Metab Res. 2010 Jan;42(1):23-30. doi: 10.1055/s-0029-1241195. Epub 2009 Oct 27.

PMID:
19862667
13.

Use of an exposure-response model to aid early drug development of an oral sphingosine 1-phosphate receptor modulator.

Rohatagi S, Zahir H, Moberly JB, Truitt KE, Inaba S, Shimozato T, Carrothers TJ.

J Clin Pharmacol. 2009 Jan;49(1):50-62. doi: 10.1177/0091270008325672. Epub 2008 Oct 23.

PMID:
18948412
14.

Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects.

Bays HE, Goldberg RB, Truitt KE, Jones MR.

Arch Intern Med. 2008 Oct 13;168(18):1975-83. doi: 10.1001/archinte.168.18.1975.

PMID:
18852398
15.

Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy.

Goldberg RB, Fonseca VA, Truitt KE, Jones MR.

Arch Intern Med. 2008 Jul 28;168(14):1531-40. doi: 10.1001/archinte.168.14.1531.

PMID:
18663165
16.

Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy.

Fonseca VA, Rosenstock J, Wang AC, Truitt KE, Jones MR.

Diabetes Care. 2008 Aug;31(8):1479-84. doi: 10.2337/dc08-0283. Epub 2008 May 5.

17.

A randomized, double-blind, celecoxib- and placebo-controlled study of the effectiveness of CS-706 in acute postoperative dental pain.

Moberly JB, Xu J, Desjardins PJ, Daniels SE, Bandy DP, Lawson JE, Link AJ, Truitt KE.

Clin Ther. 2007 Mar;29(3):399-412.

PMID:
17577461
18.

A randomized, double-blind, one-week study comparing effects of a novel COX-2 inhibitor and naproxen on the gastric mucosa.

Moberly JB, Harris SI, Riff DS, Dale JC, Breese T, McLaughlin P, Lawson J, Wan Y, Xu J, Truitt KE.

Dig Dis Sci. 2007 Feb;52(2):442-50. Epub 2007 Jan 10.

PMID:
17216336
19.

A multicenter, randomized, controlled trial to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients with osteoarthritis.

Truitt KE, Sperling RS, Ettinger WH Jr, Greenwald M, DeTora L, Zeng Q, Bolognese J, Ehrich E; Phase III Rofecoxib Geriatric Study Group.

Aging (Milano). 2001 Apr;13(2):112-21.

PMID:
11405384
20.

Identification of tyrosine phosphorylation sites in the CD28 cytoplasmic domain and their role in the costimulation of Jurkat T cells.

Sadra A, Cinek T, Arellano JL, Shi J, Truitt KE, Imboden JB.

J Immunol. 1999 Feb 15;162(4):1966-73.

21.

Mutational analysis of CD28-mediated costimulation of Jun-N-terminal kinase and IL-2 production.

Barz C, Nagel T, Truitt KE, Imboden JB.

J Immunol. 1998 Nov 15;161(10):5366-72.

23.
24.

Structural requirements for CD28-mediated costimulation of IL-2 production in Jurkat T cells.

Truitt KE, Nagel T, Suen LF, Imboden JB.

J Immunol. 1996 Jun 15;156(12):4539-41.

PMID:
8648094
25.

CD28 delivers costimulatory signals independently of its association with phosphatidylinositol 3-kinase.

Truitt KE, Shi J, Gibson S, Segal LG, Mills GB, Imboden JB.

J Immunol. 1995 Nov 15;155(10):4702-10.

PMID:
7594470
26.
27.
28.

Transmembrane signaling by the interleukin-2 receptor: progress and conundrums.

Mills GB, Schmandt R, Gibson S, Leung B, Hill M, May C, Shi YF, Branch DR, Radvanyi L, Truitt KE, et al.

Semin Immunol. 1993 Oct;5(5):345-64. Review.

PMID:
8260651
29.

Production of human monoclonal antibody in mouse ascites.

Truitt KE, Larrick JW, Raubitschek AA, Buck DW, Jacobson SW.

Hybridoma. 1984 Summer;3(2):195-9.

PMID:
6480025
30.

Characterization of human hybridomas secreting antibody to tetanus toxoid.

Larrick JW, Truitt KE, Raubitschek AA, Senyk G, Wang JC.

Proc Natl Acad Sci U S A. 1983 Oct;80(20):6376-80.

Supplemental Content

Loading ...
Support Center